Solid Phase Synthesized Dihexa Oligopeptide For Cell Culture Medium Formulation Study
180 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
HONGKONG
mm
5mg/vial,10vials/box
2027-09-27
Tirzepatide,Retatrutide,Semaglutide,GHK-Cu
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
Basic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide,GHK-Cu
-
Location:
RM 701, UNIT 108, 7/F, TWR B NEW MANDARIN PLAZA 14 SCIENCE MUSEUM RD TSIM SHA TSUI HONG KONG
-
Year of Establishment:
2026
-
-
Inquiry History180 Inquiries
Country Product Purchase Quantity Date Posted
United States
Dihexa
1 KG Oct 26, 2026
Thailand
Dihexa
1 G Oct 23, 2026
Australia
Dihexa
30 G Oct 19, 2026
Australia
Dihexa
2 G Oct 19, 2026
United States
Dihexa
100 PCS Oct 15, 2026
United States
Multi-Product Research Chemical Bulk Sourcing Inquiry
2.6 KG Oct 8, 2026
Philippines
Dihexa
1 KG Oct 2, 2026
United States
dihexa
10 MG Sep 28, 2026
Australia
Dihexa
1 MT Sep 18, 2026
United States
Dihexa
10 G Sep 9, 2026
Hungary
Dihexa
1 G Sep 7, 2026
India
Dihexa
10 MG Sep 4, 2026
Spain
Dihexa
100 MG Aug 30, 2026
Spain
Dihexa
50 MG Aug 28, 2026
United Arab Emirates
Diheza
1 G Aug 28, 2026
Norway
Dihexa
1 G Aug 26, 2026
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
SHLP2 ; PE-22-28; Dihexa ; TAK-653 ; lyophilized
10 PCS Aug 23, 2026
United States
Dihexa
1 G Aug 22, 2026
United States
Dihexa
500 G Aug 19, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Retatrutide Triple Agonist Peptide LY3437943 CAS 2381089-83-2 GLP-1/GIP/GCGR Lyophilized Solid In Stock Bulk Research Supply
Research Grade / 99%
$10-11/BOU FOB
-
-
-
-
Tripeptide Copper GHK-Cu Lab Study Raw Chemical
Pharmaceutical Grade / 99%
$22/UNIT FOB
-